Alzheimer's disease (AD) is the most common (60% to 80%) age-related disease associated with dementia and is characterized by a deterioration of behavioral and cognitive capacities leading to death in few years after diagnosis, mainly due to 
"calpain"). Although about 15 human genes (Table 1 ) of calpain family members are known to date, 13, 26 only a few of them have attracted researchers' attention. These mainly include the two isoforms, μ-calpain and m-calpain, reflecting their µM and mM Ca 2+ requirement for activation, also known as calpain-1 and calpain-2, respectively, or conventional calpains, and their only and specific endogenous inhibitor CAST. Each of the μ-calpain and m-calpain form heterodimers composed of large and small subunits ( Figure 1A ). The large protease core subunit (80 kDa molecular weight) is encoded by the CAPN1 gene for calpain-1 and CAPN2 gene for calpain-2, with about 60% homology, while the shared small regulatory (28 kDa molecular weight) subunit is encoded by CAPNS1 gene. 27 These conventional calpains have a ubiquitous distribution, in contrast to some of other unconventional calpains which expression is limited to particular tissues. Characteristic examples are the expression of calpain-3 in skeletal, calpain-6 in embryonic muscles and placenta, calpains 8 and 9 in the gastrointestinal tract smooth muscles, calpain-11 in the testes, calpain-12 in the hair follicles, and calpain-13 mostly in the lung and skin while others unconventional calpains, like calpain 5, 7, 9, and 10 have more ubiquitous distribution (Table 1) . 13, 14, 28 The large subunit of the conventional calpains is divided into four domains ( Figure 1A ). Domain I (the N-terminus) undergoes autolysis when Ca 2+ binds to this molecule, domain II (the protease core or CysPc domain)
forms the catalytic unit, domain III (the C2-like domain) has a regulatory role, and domain IV (penta-EF-hand [PEF] domain) contains the Ca 2+ -binding site. [29] [30] [31] The shared small regulatory subunit has two domains a glycine-rich (GR) domain and a calmodulin-like PEF domain 32 , respectively, representing the (domain V) and (domain VI) of the calpain heterodimer ( Figure 1A) . CAST, the third most commonly studied member of the calpain system, is a heatstable unstructured protein which according to the type of the cell has a molecular weight ranging from ∼70 to ∼140 kDa with a ubiquitous widespread expression and is conserved (>70% identical) among mammalian species. 33 The longest CAST molecule has six domains, four inhibitory homology units (CAST1-4), and two N-terminal Figure 1B ). Each of the four domains can specifically bind and effectively inhibit one calpain molecule, while the XL domain and L domain are devoid of any inhibitory potential. 34, 35 Calpains have optimum activity at around neutral pH and are regulatory rather than digestive proteases. In normal physiological cell conditions, the concentration of Ca 2+ is lower than 0.05 µM, a condition where calpains act as a biomodulator for Ca 2+ -regulated processes, including among other signal transduction, cell proliferation, cell cycle progression, differentiation, apoptosis, learning, and memory and long-term potentiation. 13, 14, 32 It was previously thought that calpain cleavage sites have a Leu or a Val residue in the P2 position, 36 but subsequent studies have shaded light on the fact that calpain-mediated truncation of its substrates is not amino acid sequencespecific but rather it is determined by the protein conformation. 37, 38 Alterations in these proteases have been linked to some human diseases collectively known as calpainopathies, thus providing evidence of the physiological functions of calpains and the indispensable role they play. Supporting this are data that highlighted that deficiencies of calpain-3 is associated with limb-girdle muscular dystrophy 2A (LGMD-2A), 39, 40 calpain-10 linked with diabetes mellites 41 , while recently calpain 5 mutation has been found to be associated with autoimmune uveitis and photoreceptor degeneration (vitreoretinopathy) 42 and calpain-14 has been associated with eosinophilic esophagitis. 43 
| CALPAIN ACTIVATION
The enzymatic activity of calpains is under the regulatory control of Ca 2+ that activates them and the endogenous protein CAST that inhibits them through a high-affinity Ca
2+
-dependent binding to the calpain. 14, 15 When Ca 2+ binds to the calpains it drives a conformational change that initiates their proteolytic properties. Calpain activity is also a measure of its autolyzed fragments. 44 Besides induction of conformational changes, Ca 2+ also induces calpains' autoproteolytic cleavage that increases its protease activity. Most of the native µ-calpain was found to be inactive until it undergoes autolysis and most of its activity is conferred to the 76 kDa fragment. 45 In the presence of Ca
, incubation of purified µ-calpain with protein kinase A (PKA) or alkaline phosphatase (AP) increased its autolysis and therefore its activity 46,47 compared with control. A 6-month chronic alcohol consumption in rats resulted in increased μ-calpain autolytic activation in skeletal muscles. 48 In another study in aging muscle, S-nitrosylation of cysteine residues of μ-calpain were observed and were suspected to be responsible for negatively regulating the autolytic activation of μ-calpain as in the absence of nitrosylation agent the μ-calpain is rapidly autolyzed due to the release of Ca 2+ from sarcoplasmic reticulum. 49, 50 Recently we have also reported an increase in calpain activity as seen by the increase in its autolyzed fragments in a hyperhomocysteinemia AD rat model. 51 The presence of phosphatidylinositol was also reported to decrease the Ca 2+ requirement for both µ-calpain and m-calpain autolysis in vitro. 52 However, autolysis was also shown to lead to the loss of proteolytic activity of both µ-calpain and m-calpain in high salt condition as they form aggregates into dimers and trimers. 53 The half in vitro maximal Ca 2+ requirement for activation of µ-calpain and m-calpain, respectively, was reported to be around 3 to 50 µM and 0.4 to 0.8 mM which are significantly higher than the cytosolic concentration found in the living cells (<0.05 µM), 13 suggesting that other mechanisms (interaction with phosphatidylinositol) are involved in the activation of these proteases. But still, the phospholipid/calpain molar ratio required for lowering the concentration of Ca 2+ required for their activation is difficult to be achieved in the living cells. 54, 55 Phosphorylation also plays a role as both conventional calpains were reported to be phosphorylated at multiple sites by kinases including PKA, protein kinase C, protein kinase G, calmodulin kinase II, and casein kinase I. 13 Phosphorylation by extracellular signal-regulated kinase (ERK) was believed to activate these proteases, specially calpain-2 is activated via direct phosphorylation at its Ser50 by ERK. 56 Supporting this were the findings that both epidermal growth factor (EGF) and brain-derived neurotrophic factor (BDNF) could activate m-calpain in hippocampal neurons dendrites by ERKmediated phosphorylation. 57 Even though phosphorylation by PKA was demonstrated to increase µ-calpain activity, 46, 47 however, others reported a decrease calpains activity 58 following PKA phosphorylation. It should also be noted that the dimerization of the two subunits is also important for the calpain activity as CAPNS1 −/− mice are embryonically lethal because both conventional calpains cannot dimerize with the small subunit indicating the crucial role of the small subunit in calpain stability. 59 Calpains have more than 100 various substrates, however, their activation in normal physiological conditions is controlled within smaller range to prevent the devastating consequences of massive proteolysis of these numerous substrates. Unfortunately, these regulatory mechanisms decrease with increase in age leading to an upregulated calpains activity implicating them in multiple conditions ranging from muscular dystrophy, diabetes, traumatic brain injury (TBI) to neurodegenerative diseases including AD.
| CALPAIN IN ALZHEIMER' S DISEASE

| Overview
Elevated calpain activity as a result of disturbances in cellular Ca 2+ homeostasis has been related to neuronal death in various neurotoxic conditions spanning from ischemia to AD. 60 Aberrant uncontrolled calpain-mediated proteolysis has been associated with various neurodegenerative diseases including AD. 13, 14, 61 τ Hyperphosphorylation and Aβ accumulation are the main markers of AD. These were found to be promoted in neuronal cells through Ca 2+ dysregulation. 62 These Ca
2+
-regulated proteases "calpains" were abnormally activated and abnormally high in AD patients' brains. 63 Other reports have shown evidence of calpain involvement in the AD pathogenesis whereby the amount of m-calpain in the cytosolic fraction of brain from AD patients is increased, 13 the ratio of autolyzed to unautolyzed µ-calpain threefold higher, and amount of CAST lowered in AD prefrontal cortex than in normal brains. 61, 64 This decrease in CAST, which results from calpain and caspase proteolysis 64 led to a subsequent decrease in the CAST/calpain ratio therefore increasing calpain activation. 44, 65 Using APP overexpressing neurons, a study demonstrated an increased activation of caspase-3 and calpain as shown by the calpain-cleaved high levels of α-fodrin and autolyzed µ-calpain fragments while these two proteases were not activated in APP mutant neurons. Furthermore, E64d a membrane permeable calpain inhibitor almost completely inhibited the neuronal caspase-3 activation and neuronal death induced by APP, an indication that high amount of wild-type APP might induce neuronal apoptosis through calpain-mediated caspase-3 activation in postmitotic neurons. 66 Upregulation of calpain activation in the brain of AD activates CDK5 through cleavage of p35 to p25 67 and its homolog p39 to p29 60 by excitotoxicity-activated calpain and CDK5 activates BACE1 promoter by binding to its target STAT3, therefore increasing BACE1 expression, Aβ40 and Aβ42 production in transgenic mice. 68 Thus, calpain overactivation leads to the two AD hallmarks, Aβ aggregates leading to SP and τ hyperphosphorylation leading to NFTs. The high amount of calpain-cleaved spectrin detected in AD patients' cerebrospinal fluid (CSF) is also suggestive of the hyperactivated calpains in the brains of these patients. 63 Abnormal calpain-2 but not calpain-1 activation was shown to be increased in NFTs and induces degradation of nicotinic acetylcholine receptor α4 thus impairing cholinergic system in AD. 69, 70 With age the central nervous system (CNS) becomes more and more susceptible to oxidative stress with widespread consequences on proteins, lipids, and nucleic acids. 71, 72 As glutamate is the main excitatory neurotransmitter in the CNS, oxidative stress-induced glutamatergic excitotoxicity lead to uncontrolled hyperactivation of NMDA receptors which increased neurons permeability to Ca 2+ and therefore injuring them.
Interestingly NMDA receptor antagonists' treatment reduced the glutamatergic excitotoxicity associated damage. 73 The resulting Ca 2+ influx in the neurons induced an increase calpain activation which through increase production of Aβ 74,75 also increases the oxidative stress thus making a circle damaging more and more neurons resulting in observed neurodegeneration in the late stage of AD.
Inflammation seen as reactive astrocytes is also a marker of AD. In line with this a study found αΙΙ spectrin breakdown product (BDP) positive astrocytes in progressive activation stages, and this spectrin BDP persists till fully reactive astrocytes. This is suggestive of the likelihood of calpains and their spectrin proteolytic activity involvement in the physiological and morphologic transformation of astrocytes from resting to reactive fibrous astrocytes. 76 In support of this overexpressing CAST in a mouse model of PD resulted in reduced calpain activity and decreased gliosis 77 and calpain inhibition by A-705053 decreased the astrocytic and microglial reactivity associated with AD-like pathology in aged 3xTg-AD mice. 78 Furthermore, Aβ deposit was found to be in association with neuronal and astrocytic Ca 2+ dysregulation. 79, 80 Treatment of cortical neurons with Aβ oligomers led to Ca 2+ influx resulting in calpain activation. 67 All these highlighted the role that calpain plays in the neuroinflammation associated with neurodegenerative diseases.
| Calpain in Aβ pathology
Aβ aggregates is one of the hallmarks of AD and Aβ oligomers aggregation process which was reported to adversely affect synaptic structure and plasticity 81, 82 highlighting the observed cognitive impairments in AD. Aβ aggregation was found to be in association with neuronal and astrocytic Ca 2+ disturbances. 79, 80 Many studies have provided evidence of the increased level and/or activity of BACE1 upon a variety of assaults like oxidative stress, 83 hypoxia, 84 
, and TBI. 86 Likewise, the level and activity of BACE1 were reported to be upregulated in AD brain, 87, 88 and this might initiate or at least worsen AD progression. On another hand the level of BACE1 and the corresponding β-carboxy terminal fragment (β-CTF) of APP were decreased in CAST overexpressing APP/PS1 mice, meaning that this could be a mechanism via which calpain activation might promote APP processing through BACE1 synthesis. 20 In support of this, is the observation that BACE1 protein levels were increased by m-calpain overexpression in HEK293 cells expressing
, and also calpain activation affected APP processing as shown by increased β-CTF production. 89 However, various calpain inhibitors led to opposite effects. 20 This indicates that downregulation of calpain suppressed the levels of BACE1, which ultimately decreased APP proteolysis and Aβ generation. BACE1 upregulation could be mediated by CDK5, which is calpain regulated through truncation of p35 to p25. 74 CDK5 activates BACE1 promoter by binding to its target STAT3, therefore increasing BACE1 level and activity, Aβ40 and Aβ42 production in transgenic mice. 68 Another experiment also reported that upregulation of calpain and p25/CDK5 resulted in phosphorylation of STAT3 (pSTAT3) which led to increase in both BACE1 and presenilin-1 (component of γ-secretase) transcription both of which are implicated in Aβ production. 90 Of particular interest is the observation that p25, a product resulting from p35 cleavage by calpain, induces the production and accumulation of Aβ in vivo, 75 presumably by increasing BACE1 transcription. 68 The phosphorylation of APP at Thr668 is believed to play a critical role in its proteolytic cleavage into soluble Aβ producing fragment. The main kinase to phosphorylate APP at this site was shown to be CDK5, 91 suggesting that the calpain-mediated activation of CDK5 also leads to the amyloidogenic APP processing both via BACE1 expression and APP Thr668 phosphorylation.
Thus, calpain activation triggered by various stressors including oxidative stress, excitotoxicity, and Aβ among other might increase the level of BACE1, which in turn promotes processing of APP and more Aβ production. In turn the upregulated Aβ levels lead to increased Ca 2+ influx and therefore increasing calpain activation. 99 Cholesterol a risk factor for AD 103 might also play a role in Aβ-mediated calcium influx through influencing NMDA receptors components and their membrane microdomain localization at synaptic sites. 104 Aβ was also found to activate NR2B-containing NMDA receptors. 105 Another way Aβ affect Ca 2+ is through the βAPP intracellular domain (AICD) which was shown to be involved in Ca 2 + signaling 106 or homeostasis in different cell culture models. 107 Advance glycation end products (AGEs) influence Aβ generation through induction of βAPP expression via oxidative stress in SHSY5Y cells 108 while injection of receptors for AGEs (RAGE) in AD transgenic mice model increases Aβ accumulation and SP formation. 109 The same study revealed an increased BACE1 expression and activity by RAGE which was mediated by AGEs or Aβ stimulation of RAGE thus increasing cytosolic Ca 2+ concentration and finally activating the transcription factor NFAT1 which leads to increased transcription of BACE1 in SHSY5Y cells. 109 The increased cytosolic Ca 2+ might also activate calpain.
Together, the data reviewed here suggest that in AD calpain and Aβ form a closed circle whereby Aβ leads to the activation of calpain, which in turn leads to a feedforward process to produce more Aβ and therefore more calpain activation.
| Calpain in τ pathology
Calpain is also involved in AD by favoring τ pathology including indirect-mediated phosphorylation and directcleavage favoring aggregation. Potential candidate τ protein kinases include CDK5 110 and GSK3. 111 Both CDK5
and GSK3β were shown to be activated by calpain. Studies have shown that, τ phosphorylation is achieved through increased activation of both CDK5 and GSK3β, the main kinases of τ, and decreasing PP2A activity, the main phosphatase of τ. Several kinases induce τ phosphorylation at over 38 Ser/Thr residues, these include ERK, CDK5, 112 GSK3β, 113 calcium/calmodulin-dependent protein kinase II (CaMKII), 114 PKA, 115 the dual-specificity tyrosine phosphorylation-regulated kinase-1A (Dyrk1A), 116 mitogen-activated protein (MAP) kinase 117 , and stressactivated protein kinases (SAPKs) 118 among others.
The most elucidated pathway of calpains involvement in AD is the calpain-mediated proteolysis of p35 to a 25 kDa form p25. Calpain was reported to cleave p35, an activator of CDK5, and generates p25 20,67,74,78 which has longer half-life than p35, and therefore is a more potent CDK5 activator, leading to a sustained activation of CDK5
and causes phosphorylation of many of its substrates. Since τ is a substrate of CDK5, it is not surprising that the p25-mediated activation of CDK5 led to τ hyperphosphorylation and the resulting NFTs formation. Furthermore, this p25 was found to accumulate in brains of AD patients, 67 suggesting that calpain-cleaved p25 is at least in part responsible for the hyperphosphorylation of τ in the intracellular NFTs observed in AD brains. 119 Moreover, the production of p25 resulted in an increased Aβ level in forebrain before any sign of neuropathology in APP transgenic mice 75 probably through upregulation of BACE1 expression. 68 Abnormal τ phosphorylation was observed in the APP/PS1 120 and this was prevented by overexpressing CAST 20 also suggesting calpain intervention.
GSK3β the other main τ kinase was also reported to be activated by calpain. 19 -dependent calpain activation. 19 It should be noted also that phosphorylation of GSK3β at Ser9 abolished the calpain-mediated cleavage at both C and N-termini while phosphorylation at Ser-389 only inhibit N-terminal cleavage.
122
CaMKII can undergo autophosphorylation (activation) in the presence of Ca 2+ , 123 was shown to be a τ kinase and has a role in memory and neuroplasticity. 114 However, its redistribution or prolonged activation could implicate it in AD. In support, a correlation with cognitive dysfunction in MCI and AD subjects was found with the reduction of T286-autophosphorylation in apical dendrites of granule cells of the DG. 124 Resveratrol was shown to decrease τ hyperphosphorylation via suppression of GSK3β and CaMKII activities in N2A cells exposed to formaldehyde.
125
Strong and sustained stress-like acute severe CO poisoning could lead to both calpain and CaMKII expression and activation. 126 Calpain might also induce Ca 2+ as revealed by studies where increased expression of µ-calpain resulted in mitochondrial damage 127 with consequent production of reactive oxygen species (ROS) which in turn resulted in a significant Ca 2+ increase 128 and thus activation of CaMKII. Via membrane skeleton protein degradation calpain was also shown to be upstream activator of CaMKII resulting in ischemia/reperfusion (IR) injury. 129 Interestingly CaMKs family are shown to be substrates of calpain. More specially calpain-mediated CaMKIV activation is characterized in the apoptosis of SHSY5Y cells 130 and cerebellar granule cells, 131 while mcalpain was shown to activate CaMKII-gamma which in turn led to cAMP/PKA-mediated ERK1/2 phosphorylation resulting in caspase-3-mediated apoptosis in head kidney macrophages. 132 It should also be noted that CaMKII plays an antiapoptotic.
PKA is also reported to be a τ kinase as revealed by the study where cAMP-dependent PKA phosphorylation of τ at serine 214 was observed in monkey 133 and SHSY5Y cells. 134 PKA activator forskolin was shown to induce τ phosphorylation at Thr231. 115 In addition, an in vitro study showed that in the presence of Ca 2+ incubation of μ-calpain with PKA resulted in more autolysis than control, but lower than the AP group. Furthermore, PKA was found to catalyze μ-calpain phosphorylation at serine 255, 256, and 476, and upregulated μ-calpain activity. 46, 47 Together this could lead to the downstream of calpain including Aβ and τ pathologies. However, another study
showed that the degradation of calpain substrate proteins was higher in AP-treated sample and less in PKA-treated ones. 135 Both APP and τ were reported to be substrates of Dyrk1A, therefore Dyrk1A is linked to the two main hallmarks of AD. Dyrk1 inhibition rescued the observed cognitive deficits in 3xTg-AD mice with a concomitant reduction in Aβ and τ pathology 136 via decreasing phosphorylation of both APP and insoluble τ, thereby increasing APP metabolism and decreased Aβ levels. 137 DYRK1A phosphorylates τ on 11 different Ser/Thr residues many of which are found in NFTs of AD, 116 and its overexpression led to increased 3R-τ and decreased 4R-τ. 138 This is mediated through influence on the alternative slicing of τ exon 10. 139, 140 Inhibition of Dyrk1A by Leucettine L41 141 or EHT 5372 142 mitigated both τ and Aβ pathologies. Interestingly Dyrk1A was reported to be truncated at the MAHAMAN ET AL.
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C-terminus and this was associated with increased µ-calpain activity in AD brain. Moreover, in vitro studies revealed that µ-calpain proteolyzed Dyrk1A at both C and N termini and enhanced its τ kinase activity, with C-terminus truncation producing Dyrk1A with a stronger activity than its full-length protein in promoting τ phosphorylation and exon 10 exclusion. 143 Creatine kinase (CK) is found in many tissues including brain, cardiac, and skeletal muscles. The creatine/ phosphocreatine system which is under the regulation of CK, plays an important role in energy metabolism therefore very important for neuron. It is well known that energy metabolism and the CK function are affected in AD brain and in cells exposed to the Aβ peptide. 144 Creatine was also focally detected in hippocampi from APP transgenic mice and postmortem AD patients brain and was suggested to be a marker of the disease, 145 probably due to a decreased CK activity. Supporting this, other studies also found a decrease in this enzyme and proposed that this could due to oxidative damage as CK is sensitive to oxidative stress. 146, 147 Moreover, CK was also found to be a calpain substrate. 148 Accordingly, another study reported a decrease in CK activity with increased calpain activity 149 suggesting the degradation of this enzyme by calpain. Furthermore, calpain inhibition was shown to prevent cell death in IR, via decreasing DNA strand breaks and CK release, suggesting calpain is an upstream of CK.
150,151
Calpains also activates ERK/MAP kinases 152 and other kinases that are also involved in τ phosphorylation. Both calpain and ERK1,2 were found to be activated along with concomitant neurofilament phosphorylation and interestingly the inhibition of calpain by calpeptin abolished both neurofilament phosphorylation and ERK1,2 activation, while inhibiting ERK1,2 by a specific inhibitor Meck1,2 had no effect on calpain activation suggesting calpain to be an upstream activator of the ERK/MAP pathway. 152 To induce τ phosphorylation, calpain could also directly or indirectly affect phosphatases. PP2A account for most of the dephosphorylation activity of τ, however protein phosphatase 1 (PP1) also play a part. Therefore, even though it was shown to be neuroprotective, the degradation of PP1 mediated by µ-calpain 153 might increase τ phosphorylation as seen in AD. Calpain was also shown to mediate the cleavage of the PP2A regulatory subunit α4 leading to the proteasomal degradation of PP2Ac resulting in τ hyperphosphorylation. 154 GSK3β one of the main kinase of τ is known to be truncated by calpain leading to its increased activity. The underlying mechanism is reported to be its translocation to the nucleus and its enhanced interaction with PP2A upon truncation, promoting its Ser9 dephosphorylation and thus increasing its activity 155 highlighting an indirect intervention of calpain on PP2A-mediated activation of this kinase and involvement in AD. Also, extra-synaptic N-methyl-D-aspartate receptor (NMDAR) activation led to neuronal death as a result of degradation of striatal-enriched protein tyrosine phosphatase (STEP) mediated by calpain. 153 Tyrosine phosphatase (PTPN13) is reported to dephosphorylates and inhibits c-Abl (τ kinase) but also to be a substrate of m-calpain which inactivates its phosphatase activity. 156 Calpain was also reported to induce the degradation of inositol polyphosphate-4-phosphatase (INPP4), 157 a negative regulator of the phosphoinositide 3-kinase (PI3K) signaling pathway. 158 PI3K is known to phosphorylate GSK3β at Ser9 inhibiting its kinase activity. 159 Thus, by degrading INPP4 and PTPN13, calpain might respectively increase the kinase activities of GSK3β and c-Abl, therefore increasing τ phosphorylation and accumulation.
Besides τ phosphorylation, another way calpain activation play a role in τ-mediated neurodegeneration is through inducing τ cleavage. [160] [161] [162] [163] [164] But this cleavage might be at earlier stage of the disease since hyperphosphorylation makes τ, which normally is rapidly cleaved by the calpains, 13,165 highly resistant to calpain truncation, 166, 167 so the NFTs in AD are resistant to calpain 168 suggesting phosphorylation might regulate τ susceptibility to calpain. Hence, because neurofilament proteins are good substrates of calpains, it may play an important role in the AD observed necrotic neuronal death. Therefore, small fragments of τ, which were believed to be generated by calpain-1 proteolysis, have been observed in Aβ-treated hippocampal neurons and these fragments of around 17 kDa (τ 45 to 230) are neurotoxic. 162, 163 Another study also reported the presence of these types of fragments in the neocortex of AD brains as well as in brain areas affected by other tauopathies and their levels correlated with increased calpain activity. 167 Furthermore, these 17 kDa τ fragments induced neuronal cell death even in the absence of Aβ oligomers following their expression in neuronal and nonneuronal cell types or in an in vivo drosophila model system. 162, 163, 169 Fragmented τ has also been found in mitochondria present in synaptosomal fraction from AD brain and the level of these fragments were found to be reduced in culture neurons treated with calpain inhibitors. 160 These types of fragments were reported to induce mitochondrial dysfunction. 164 By the way it could be also noted that calpain-2 activation generates smaller τ fragments with nonobservable neurotoxic effects in CNS neurons. 161 Collectively, these data strongly provided evidence of the deleterious role of calpain in τ hyperphosphorylation and generation of neurotoxic τ fragments in neurodegeneration. lead not only to impaired autophagy and buildup of harmful proteins but also to lysosomal rupture/ permeabilization leading to release of lysosomal enzymes and cell death in both IR and AD brains. 23, 176, 177 Moreover, LAMP2a a molecular marker for lysosome stability and an essential component of chaperone-mediated autophagy, 178 was also reported to be cleaved by calpain leading to lysosomal rupture and cell death. 24 Also, downregulation of LAMP2a via RNAi, led to impaired lysosomal degradation of long-lived proteins and chaperonemediated autophagy substrates in neuronal systems. 179 Hsp70.1 was also shown to attenuate τ toxicity via maintaining τ in its soluble nonaggregated nature and by facilitating its degradation. [180] [181] [182] Thus, impaired Hsp70.1 function as a result of carbonylation and/or cleavage, as a result of calpain activation, could lead not only to lysosomal destabilization but also τ aggregation and NFTs formation. 182, 183 Together these suggested that cleavage of Hsp70.1 and LAMP2a is another way that calpain contributes to neurodegenerative changes in AD and related conditions.
| Calpain in autophagy/lysosomal impairment
| Calpain in synaptic dysfunction
Among calpain substrates are included both presynaptic and postsynaptic proteins, so it is not surprising that calpain is implicated in synaptic dysregulation. Accumulating evidence have been provided by many studies as per the abnormal activation of calpains not only favors Aβ accumulation and τ hyperphosphorylation in neurons but also is implicated in the development of synaptic pathology in neurodegenerative diseases including AD. 77, 78, 184 Overactivation of calpain in the brain of transgenic mice, induced a myriad of AD pathological markers including βAPP processing, amyloid deposits, τ phosphorylation, activation of astrocytes, synapse loss, and cognitive impairment. 20, 63, 77 These synaptic dysfunctions seen as synaptic loss seems to significantly correlate with the functional and cognitive deficits observed in different stages of AD. 185 Supporting this is a report from a study, where the calpain involvement in synaptic loss is highlighted by its cleavage of proteins in the presynaptic termini and/or the postsynaptic elements, thus leading to functional changes MAHAMAN ET AL.
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in affected brain areas. 186 Using cell culture and animal models of AD Aβ was recently shown to induce a significantly reduced level of dynamin-1, a neuron-specific GTPase highly enriched in presynaptic terminals which function is to detach synaptic vesicles from the membrane so that they can reenter the synaptic vesicle pool and be refilled for future release. 187 This decrease in dynamin protein lead to the depletion of synaptic vesicles and the accumulations of empty pouches at presynaptic termini, thus leading to synaptic dysfunction. This Aβ-mediated dynamin-1 reduction was believed to be in part due to calpain-mediated proteolysis. 99, 188 At the postsynaptic element, calpain hyperactivation resulted in the degradation of several proteins changing the ultrastructure of the postsynaptic density (PSD). Following this event are the accelerated cleavage of PSD95 and the NMDA receptor subunits NR1 and NR2A and 2B. 189, 190 Calpain was shown to also exacerbate NMDA neurotoxicity by cleaving mGluR1. 191, 192 Additionally, calpain activation induces the cleavage of PKA leading to a decrease in both its regulatory and the catalytic subunits thus decreasing the activity of CREB, an important memory-related protein, aggravating synaptic dysfunction 193 as seen by the resulting memory impairment. In a mouse model of PD overexpressing CAST the observed decreased calpain activity was found to be accompanied by a concomitant reduction of the cleaved synaptic protein α-synuclein ameliorating the observed neurodegeneration. 77 In support, using calpain inhibitor A-705053 treatment in 3xTg-AD mice model significantly increased the levels of synapsin-1 and PSD95 to nontransgenic animal level thereby ameliorating the synaptic loss observed in these AD mice model. 78 All of these revealed the undeniable role that calpain played in synaptic pathologies.
| Calpain in learning and memory
Many studies have provided data concerning the calpain-mediated dysregulation of learning and memory-related molecules in AD including ERK, CREB, and DARPP-32 among others. CREB, a key player in learning and memory and synaptic plasticity, and a core component involved in converting short-term to long-term memory, 21 has been found to be dysregulated in various neurological disorders, including AD, Huntington's disease, Parkinson's disease, ischemia, and addiction. 194, 195 In line with this ERK and CREB phosphorylation (activation) were reported to be decreased in transgenic AD mouse model, 20, 184 while overexpression of the endogenous calpain inhibitor CAST prevented this decrease with concomitant improvement in learning and memory ability in these animals. 20 Also, selectively inhibiting calpain-2 by C2-I resulted in an improved state of learning and memory through increasing timely activation of ERK. 196 DARPP-32 is a key player involved in the regulation of the PKA-CREB signaling pathway. 197 An increase in the cAMP level leads to the activation of PKA and phosphorylation of DARPP-32 at Thr34, which inhibits PP1 a key phosphatase of CREB, therefore increasing CREB phosphorylation. 198 Interestingly, in AD brains DARPP-32 protein level was found to be about 20% lower compared with control brains, however two fragmented forms, about 28 and 4 kDa, of DARPP-32 were found in high amount in AD brains. 18 Cleavage of DARPP-32 protein was also reported in both OA or Aβ peptides treated SHSY5Y cells and primary neurons along with a simultaneous decrease in CREB phosphorylation ultimately resulting in synaptic abnormalities. 18 Consistently, calpain inhibition reversed the DARPP-32 truncation in the OA-treated neurons while recombinant DARPP-32 was cleaved by calpain in an in vitro assay. 18 In support of this, restoring CREB phosphorylation through calpain inhibition has been reported to ameliorate synaptic transmission and memory in an AD mouse model. 184 This is in accordance with the findings that calpain affects CREB kinases such as PKA and CaMKII.
These data together suggested that in AD, calpain-mediated DARPP-32 truncation and activation of PP1 might be involved in the impairment of the PKA-CREB signaling pathway and therefore impairing learning and memory ability in the affected subject. It is worth noting that, in normal physiological conditions, calpain also play an important role in synaptic plasticity and thus a positive regulator of learning and memory. 199, 200 Recently it was reported that calpain-1 and calpain-2 are implicated in learning and memory via two opposing effects where calpain-1 was found to positively affect LTP and learning and memory while calpain-2 restricted the extent of learning and memory. 196, 201 Thus, calpains are essential for life but their uncontrolled hyperactivation is destructive and implicate them in the etiopathology of many diseases conditions including AD.
| CALPAIN INHIBITORS AS AD THERAPY
The undeniable role that calpains play in AD progression and pathogenesis made it a potential target for therapeutics, and thus has stimulated the development of many calpain inhibitors for AD treatment. Various insults to the CNS activate calpain, leading to Aβ production, τ hyperphosphorylation, synaptic dysfunction, and neuronal degeneration. 13 Upregulated calpain activity due to Ca 2+ influx or decrease of CAST causes the proteolysis of many functional proteins in the brain. 84, 202, 203 Together, this implies that calpain play a multistage role in AD progression from the earlier APP processing via BACE1 activation to the later CDK5 and GSK3β activation, the resulting τ hyperphosphorylation, autophagy impairments, synaptic and neuronal dysfunction, and the finally observed neurodegeneration (Figure 2) . Thus, calpain inhibition could be a potential option in preventing neuronal degeneration induced by multiple neurotoxic factors.
A study by Trinchese et al 184 showed that synthetic calpain inhibitors improved memory and synaptic transmission without significant effects on Aβ deposit in APP/PS1 mice. Considering that synthetic calpain inhibitors are not highly specific, they might affect other proteases and therefore may influence neurodegeneration processes. Thus, inhibiting calpain by overexpressing its endogenous inhibitor CAST would be a better way to study isolated calpain effect. Interestingly, CAST overexpression in APP/PS1 (APP/PS1/CAST), 20 APP23 (APP23/ CAST), 204 APP (APP/CAST), 63 and JNPL3 (CAST/JNPL3) 205 mice led to a significant decrease in Aβ level and/or τ phosphorylation and this effect appeared to be mediated through decreasing BACE1 and β-CTF levels. This
CAST-mediated inhibition of calpain in the nervous system is more responsive in pathological conditions. 204 Similar F I G U R E 2 Summary of calpain involvement in AD pathology. Intracellular calcium influx resulting from increase oxidative stress, increased NMDAR activation and other assaults together lead to increased and uncontrolled calpain activation. This calpain hyperactivation could also result from impaired regulatory mechanisms like decreased calpastatin level which could also be a result of calpain proteolysis. The resulting calpain upregulation then lead to truncation and increased GSK3β activation, cleavage of p35 to p25 with resulting prolonged CDK5 activation. On one hand these two (GSK3β and CDK5) lead to τ hyperphosphorylation, while on the other hand, the prolonged CDK5 activation lead to increase BACE1 expression and activation via STAT3 with consequent increased Aβ production. The τ hyperphosphorylation and Aβ deposit together lead to synaptic dysfunction and neurodegeneration. The Aβ peptides could also exert a positive feedback leading to increased oxidative stress and/or increased calcium influx and more calpain activation and the cycle continues. AD, Alzheimer's disease; Aβ, amyloid beta; BACE1, beta APP cleaving enzyme 1; GSK3β, glycogen synthase kinase 3β; NMDAR, N-methyl-D-aspartate receptor effects with CAST overexpression have also been demonstrated with synthetic inhibitors as they also suppressed calpain and reduced BACE1 levels, which attenuated APP processing and therefore Aβ generation. 20 However, stimulation and activation of calpain by various stressors 20 or CAST knock-out 63 caused the opposite effects.
Additionally, the CAST overexpression also prevented astrocyte activation, microgliosis, and synapse loss. 20 213 This novel calpain inhibitor A-705053, which can easily be taken orally, has improved pharmacokinetics and has provided interesting results as it was shown to prevent calpain-mediated truncation of dynamin-1 and τ in primary hippocampal neurons culture. 188 It was also effective when used as preventive, simultaneous, or curative treatment against Aβ-triggered neurodegenerative process 188 and prevented neurodegeneration of the nucleus basalis magnocellularis induced by Aβ oligomer. 214 A-705053 was reported to reduce both Aβ40 and Aβ42 and also decreased the thioflavin-s positive Aβ aggregates through decreasing BACE1 and increasing ATP-binding cassette transporter A1 (ABCA1) expression, which respectively decrease the production and increase the clearance of Aβ 78 and also inhibited Aβ-induced synaptic deficits 214, 215 and prevented in vitro and in vivo stress-induced hyperphosphorylation of τ. 216 Unfortunately, this calpain inhibitor also has limited selectivity against other cysteine protease cathepsins B, K, L, S, and C thus preventing further investigation on this compound. 217 Moreover, inhibition of cathepsins C, L, and S might induce serious side effects like immunosuppression while inhibition of cathepsins B and K is not detrimental. [218] [219] [220] [221] This idea led to the very recent discovery of new calpain inhibitors derived from A-705053 which retain the calpain inhibitory effect and with more selectivity. These compounds, A-933548 and A-953227, more specially the later, have more preclinical safety with in vivo anti-AD profiles. 217 But still further experiments are needed before considering the use of this calpain inhibitor as potential therapeutic treatment. Other recent developments result from another study that showed that inhibiting calpain-2 by its selective inhibitor C2-I enhanced learning and memory in both normal and genetically memory impaired mice by prolonging ERK activation. 196 Another report revealed the downregulatory effect of both τ hyperphosphorylation and Aβ peptide production of synthetic chalcone derivatives 222 conferring them a neuroprotective effect via decreasing p-MAPK and BACE1 protein levels. Two other calpain inhibitors NYC438 and NYC488, have also been developed and showed promising results and had proven efficacy, potency, and safety. 223 Collectively this suggested the promising potential of inhibiting calpain in AD therapeutics.
| FUTURE DIRECTIONS
The two main hallmarks of AD are well established to be Aβ aggregate into SP and τ hyperphosphorylation forming NFTs. These are accompanied by a decline in cognitive functions including impaired memory and behavioral deficits. With Aβ deposit as the trigger of the disease, many of the primary AD therapies have focus on reducing Aβ load in the affected brain areas. Many of these strategies including monoclonal antibodies treatment against Aβ, vaccination with Aβ, Aβ aggregation inhibitors, β-secretase interference, nerve growth factors, just to mention these, have succeeded in reducing the Aβ burden but often failed to improve the cognitive deficit and the resulting neurodegeneration. Considering this and also considering the fact that NFTs correlate more with the degree of the disease, therapeutic strategies that target both Aβ and τ hyperphosphorylation would be more efficient in treating the disease. From the summarized data above, it is clear that calpain hyperactivation is a big player in the generation and/or exacerbating these two AD hallmarks. Thus, targeting calpain either through downregulation or inhibition could be a way out. As reviewed earlier inhibiting calpain through overexpression of its endogenous inhibitor CAST and through the use of different synthetic inhibitors have provided promising results in neurodegenerative animal and cell models for the treatment of this conditions.
Calpain gene deletion has been proven to be lethal 224 however suppression of calpain-1 expression using specific probes prevented cell injury in human hepatic cancer cell lines induced by oxidative stress. 225 In AD cell model other calpain inhibitors leupeptin, BDA-410 and E64, have shown protective effects against cell death, 78,162,211,212 while MDL28170 had protective effect against excitotoxicity. 191, 210 It is unfortunate to note that most of the currently used calpain inhibitors in AD therapeutics are limited due to their physical and/or chemical properties resulting in inefficient cellular penetration, selectivity, and kinetics. However, hope in this quest occurs from recent development of newly synthetic inhibitors, like A-705053, A-933548, A-953227, NYC438, NYC488, and chalcone derivatives which have proven efficacy. 78, 188, 213, 214, 217, 222, 223 Moreover, preliminary studies using these inhibitors in mouse and rat models of AD provided interesting results recovering cognitive functions when treatment was administered at an early age in these animals. 18, 212, 214 Taken together, the data reviewed in this literature highlighted the undeniable involvement of calpain upregulation in AD pathology and the potential hope that reside in the development of calpain inhibitors as AD therapeutic tool and related neurodegenerative diseases. But there is still a long way to go in establishing the specificity, efficacy, safety, availability, and adequacy in the inhibitory effect of these compounds for the use in clinical trials and for the subsequent consideration for long-term AD treatment, since calpains also play a normal physiological role as mentioned above. Supporting this is also a study where calpain inhibition led to the impairment of insulin release. 226 It should also be noted that recent developments have provided evidence on the differential involvement of calpains in learning and memory and neurodegeneration where calpain-1 has been reported to enhance learning and memory and neuroprotective while opposite effects have been attributed to calpain-2.
196,201
Thus, specific targeting of these isoforms should be considered under different pathological conditions.
Clear and palpable evidence are provided from innumerable studies ranging from cell models to AD patients passing through animal models on the uncontestable role that upregulation of calpain plays in the pathogenesis of numerous neurodegenerative diseases among AD. This triggered a quest for the development of strategies aiming in decreasing calpain activity as treatment of AD and other neuronal injuries involving calpain hyperactivation. The result of this is the synthesis of numerous calpain inhibitors. However, many of these inhibitors are limited because of their insufficient cellular penetration, selectivity, and kinetics. Non-the-less, the idea that calpain inhibition could be a potential therapeutic strategy in neurodegenerative diseases still remain one of the promising option as supported by evidence from in vitro, in culture, and animal model studies using calpain inhibitors like MDL28170, A-705053, A-953227, NYC438, and NYC488 among others. However, it should be noted that these experiments were conducted in controlled environments with less or minimal influence of age-related chronic diseases and in less complex organisms than humans.
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